While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target ...

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

Barclays analyst Peter Lawson maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report) yesterday and set a price target of ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $74.00 price ...